clinical investigation of brain microstructure of moyamoya disease

clinical investigation of brain microstructure of moyamoya disease - diffusion MRI of Moyamoya Disease

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000027949

Enrollment

320

Registered

2017-06-27

Start date

2017-06-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

moyamoya disease

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) inclusion criteria of patients: 1. 6 to 64 years old who can undergo MRI without sedative agents 2. diagnosed as bilateral or unilateral moyamoya disease according to diagnostic guidelines 3. no neurological deficit affecting the scores of neurophysiological tests (aphasia, agnosia etc) 4. modified Rankin scale of 0 to 2 5. informed consent obtained from patients and parents of patients under age (2) inclusion criteria of normal healthy volunteers: 1. 16 to 64 years old 2. no neurological deficit affecting the scores of neurophysiological tests (aphasia, agnosia etc) 3. modified Rankin scale of 0 to 3 4. no history of neurological disease

Exclusion criteria

Exclusion criteria: 1. patients with quasi-moyamoya disease 2. contraindication of MRI examination (e.g. metal implants such as cardiac pacemaker) 3. brain lesion other than moyamoya disease affecting MRI parameters (e.g. brain tumor, venous angioma) 4. judged as inappropriate from other reasons (e.g. metal implants affecting MRI signals, clinical signs of depression or dementia, systemic disease such as terminal carcinoma, cirrhosis, renal insufficiency)

Design outcomes

Primary

Measure	Time frame
1. Comparing MRI parameters (ADC, FA, Vic, Viso and OD of NODDI, and MTsat) with scores of neurophysiological tests( WISC or WAIS, WCST, stroop test, word fluency test, TMT, and the BIg Five Personal Inventory or NEO-FFI)	—

Secondary

Measure	Time frame
2. Comparing MRI parameters (ADC, FA, Vic, Viso and OD of NODDI) of patients with moyamoya disease and of age-sex matched normal healthy volunteers. 3. Comparing MRI parameters (ADC, FA, Vic, Viso and OD of NODDI and MTsat) and 15Ogas PET (CBF, CBV, OEF, MTT and CMRO2).	—

Countries

Japan

Contacts

Public ContactShoko Hara

Tokyo Medical and Dental Univeristy Department of Neurosurgery

shara.nsrg@tmd.ac.jp03-3813-6111

Outcome results